HSP90B1 and central nervous system cancer: In addition, HSP90B1 expression levels were significantly higher in GBMs (WHO grade IV) than those in gliomas of lower grades (including grades II and III), which has been suggested to be benefited from IR-based therapies (Supplementary Fig. 2C, available online).